Compare COMP & ACAD Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | COMP | ACAD |
|---|---|---|
| Founded | 2012 | 1993 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | EDP Services | Biotechnology: Pharmaceutical Preparations |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 4.9B | 4.6B |
| IPO Year | 2021 | 2004 |
| Metric | COMP | ACAD |
|---|---|---|
| Price | $10.33 | $27.28 |
| Analyst Decision | Strong Buy | Buy |
| Analyst Count | 9 | 21 |
| Target Price | $10.39 | ★ $29.24 |
| AVG Volume (30 Days) | ★ 12.7M | 1.5M |
| Earning Date | 11-04-2025 | 11-05-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 98.53 |
| EPS | N/A | ★ 1.54 |
| Revenue | ★ $6,642,200,000.00 | $1,047,118,000.00 |
| Revenue This Year | $25.14 | $15.16 |
| Revenue Next Year | $12.29 | $11.42 |
| P/E Ratio | ★ N/A | $17.80 |
| Revenue Growth | ★ 24.27 | 12.69 |
| 52 Week Low | $5.10 | $13.40 |
| 52 Week High | $11.03 | $27.61 |
| Indicator | COMP | ACAD |
|---|---|---|
| Relative Strength Index (RSI) | 67.68 | 76.30 |
| Support Level | $10.32 | $22.81 |
| Resistance Level | $10.94 | $25.20 |
| Average True Range (ATR) | 0.41 | 0.86 |
| MACD | 0.00 | 0.31 |
| Stochastic Oscillator | 63.09 | 96.35 |
Compass Inc provides an end-to-end platform that empowers residential real estate agents to deliver exceptional service to seller and buyer clients. The platform includes an integrated suite of cloud-based software for customer relationship management, marketing, client service and other critical functionality, all custom-built for the real estate industry and enabling core brokerage services. Business operations are conducted in the United States and earn revenue domestically.
Acadia Pharmaceuticals Inc is a biopharmaceutical company focused on the development and commercialization of medicines that address unmet medical needs in central nervous system (CNS) disorders and rare diseases. It has two core franchises in neuroscience and neuro-rare diseases. The neuroscience franchise is anchored by its commercial product NUPLAZID (pimavanserin), which is used for the treatment of hallucinations and delusions associated with Parkinson's Disease Psychosis (PDP). The neuro-rare disease franchise is anchored by the commercial product DAYBUE, which is used for the treatment of Rett syndrome. In addition, the company has various product candidates under development in different stages, including ACP-204, ACP-101, ACP-211, ACP-711, ACP-2591, etc.